Biotech entity
Food and Drug Administration is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 53-day span, the pace is roughly 0.3 stories per week. Source depth averages 4 original sources per story, versus 3.9 across the same-window beat baseline.
Last mentioned: Aug 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Food and Drug Administration is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 53-day span, the pace is roughly 0.3 stories per week. Source depth averages 4 original sources per story, versus 3.9 across the same-window beat baseline. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The 6.5 average consequence score is above the beat benchmark of 6.1 in the same window. We currently track 2 Biotech stories that mention Kyle Diamantas, published between June 28, 2026 and August 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 257 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kyle Diamantas. Shared-story counts are live from our verified record — not editorial picks.
Biopharma's key regulator is set to change hands as Trump nominates Heidi Overton, architect of drug-pricing negotiations and vaccine-schedule revisions. Developers and investors are assessing what her confirmation means for approval timelines, pricing pressure, and regulatory predictability.
Source: nbcwashington.com · kfbk.iheart.com
HHS Secretary Kennedy warns that Chinese companies accounted for nearly half of global pharmaceutical licensing deals in 2025, prompting FDA actions to streamline early-stage trials and potentially reduce drug development times by 6 to 12 months. The shift could reshape US biotech competitiveness and investment returns.
Kyle Diamantas is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
